Cargando…

Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins

N-glycosylation is a complex post-translational modification with potential effects on the efficacy and safety of therapeutic proteins and known influence on the effector function of biopharmaceutical monoclonal antibodies (mAbs). Comprehensive characterization of N-glycosylation is therefore import...

Descripción completa

Detalles Bibliográficos
Autores principales: Higel, Fabian, Seidl, Andreas, Demelbauer, Uwe, Sörgel, Fritz, Frieß, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171024/
https://www.ncbi.nlm.nih.gov/pubmed/24848368
http://dx.doi.org/10.4161/mabs.29263
_version_ 1782335873101070336
author Higel, Fabian
Seidl, Andreas
Demelbauer, Uwe
Sörgel, Fritz
Frieß, Wolfgang
author_facet Higel, Fabian
Seidl, Andreas
Demelbauer, Uwe
Sörgel, Fritz
Frieß, Wolfgang
author_sort Higel, Fabian
collection PubMed
description N-glycosylation is a complex post-translational modification with potential effects on the efficacy and safety of therapeutic proteins and known influence on the effector function of biopharmaceutical monoclonal antibodies (mAbs). Comprehensive characterization of N-glycosylation is therefore important in biopharmaceutical development. In early development, e.g. during pool or clone selection, however, only minute protein amounts of multiple samples are available for analytics. High sensitivity and high throughput methods are thus needed. An approach based on 96-well plate sample preparation and nanoLC-MS of 2- anthranilic acid or 2-aminobenzoic acid (AA) labeled N-glycans for the characterization of biopharmaceuticals in early development is reported here. With this approach, 192 samples can be processed simultaneously from complex matrices (e.g., cell culture supernatant) to purified 2-AA glycans, which are then analyzed by reversed phase nanoLC-MS. Attomolar sensitivity has been achieved by use of nanoelectrospray ionization, resulting in detailed glycan maps of mAbs and fusion proteins that are exemplarily shown in this work. Reproducibility, robustness and linearity of the approach are demonstrated, making use in a routine manner during pool or clone selection possible. Other potential fields of application, such as glycan biomarker discovery from serum samples, are also presented.
format Online
Article
Text
id pubmed-4171024
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-41710242015-07-01 Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins Higel, Fabian Seidl, Andreas Demelbauer, Uwe Sörgel, Fritz Frieß, Wolfgang MAbs Report N-glycosylation is a complex post-translational modification with potential effects on the efficacy and safety of therapeutic proteins and known influence on the effector function of biopharmaceutical monoclonal antibodies (mAbs). Comprehensive characterization of N-glycosylation is therefore important in biopharmaceutical development. In early development, e.g. during pool or clone selection, however, only minute protein amounts of multiple samples are available for analytics. High sensitivity and high throughput methods are thus needed. An approach based on 96-well plate sample preparation and nanoLC-MS of 2- anthranilic acid or 2-aminobenzoic acid (AA) labeled N-glycans for the characterization of biopharmaceuticals in early development is reported here. With this approach, 192 samples can be processed simultaneously from complex matrices (e.g., cell culture supernatant) to purified 2-AA glycans, which are then analyzed by reversed phase nanoLC-MS. Attomolar sensitivity has been achieved by use of nanoelectrospray ionization, resulting in detailed glycan maps of mAbs and fusion proteins that are exemplarily shown in this work. Reproducibility, robustness and linearity of the approach are demonstrated, making use in a routine manner during pool or clone selection possible. Other potential fields of application, such as glycan biomarker discovery from serum samples, are also presented. Landes Bioscience 2014-07-01 2014-05-21 /pmc/articles/PMC4171024/ /pubmed/24848368 http://dx.doi.org/10.4161/mabs.29263 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Report
Higel, Fabian
Seidl, Andreas
Demelbauer, Uwe
Sörgel, Fritz
Frieß, Wolfgang
Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title_full Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title_fullStr Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title_full_unstemmed Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title_short Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins
title_sort small scale affinity purification and high sensitivity reversed phase nanolc-ms n-glycan characterization of mabs and fusion proteins
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171024/
https://www.ncbi.nlm.nih.gov/pubmed/24848368
http://dx.doi.org/10.4161/mabs.29263
work_keys_str_mv AT higelfabian smallscaleaffinitypurificationandhighsensitivityreversedphasenanolcmsnglycancharacterizationofmabsandfusionproteins
AT seidlandreas smallscaleaffinitypurificationandhighsensitivityreversedphasenanolcmsnglycancharacterizationofmabsandfusionproteins
AT demelbaueruwe smallscaleaffinitypurificationandhighsensitivityreversedphasenanolcmsnglycancharacterizationofmabsandfusionproteins
AT sorgelfritz smallscaleaffinitypurificationandhighsensitivityreversedphasenanolcmsnglycancharacterizationofmabsandfusionproteins
AT frießwolfgang smallscaleaffinitypurificationandhighsensitivityreversedphasenanolcmsnglycancharacterizationofmabsandfusionproteins